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Abstract: The unique properties of nanomaterials related to structural stability and 
  quantum-scale reactive properties open up a world of possibilities that could be exploited to 
design and to target drug delivery or create truly microscale biological sensors for veterinary 
applications. We developed cost-saving and solvent-free nanoemulsions. Formulated with a low-
energy method, these nanoemulsions can find application in the delivery of controlled amounts 
of drugs into the beverage of breeding animals (such as poultry, cattle, pigs) or be used for the 
controlled release of injectable poorly water-soluble drugs.
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Introduction
Comparative medicine has seen resurgence over the past 10 years largely because of the 
growth of evidence-based veterinary medicine and the gain in knowledge acquired from 
comparative genomics. Diseases such as diabetes, hypertension, skin atrophy, and cancer 
in some pet animals are similar to those in humans, which enables parallel development 
of therapeutic approaches. The synergy inherent to a single medicine could result in 
significant cost-savings for product development for both animals and humans.
A number of factors that must be taken into consideration when assessing what 
might emerge as new animal drug products in the future. These factors revolve around 
economic, societal, and technological issues. However, economic and societal aspects 
are decisive factors in business decisions, as without a market, new products will not be 
developed. Projection of transforming Transformational technologies such as analytical 
chemistry, computational sciences, molecular biology, genomics, and material engineer-
ing are key predictors of future developments. Economic, societal, and technological 
issues have led to pharmacology research for the treatment of conditions such as aggres-
sive behavior, separation anxiety, or obsessive–compulsive disorder and the launch of 
dirlotapide, a drug targeted to reduce obesity in dogs, 4 years ago. The future trends for 
the pet animal market seem to be getting more sophisticated. Moreover, the pet animal 
market and animal health products have slim profit margins. Global competition for 
food is intense, reducing marginal return rates. In order to improve the quality of animal 
health, future developments will take into account the following:
1.  Continued advances in pharmaceutical technology;
2.  Nanotechnology;
3.  General increased ability to control and target drug delivery;
4.  Increased knowledge of pharmacogenomics.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Nanotechnology, defined as manufacturing materials that 
are ,100 nm in one dimension and having unique physical 
properties due to this size, was first designed for human appli-
cations. At present, developing nanotechnologies for pets 
and farm animal markets seems to be a real opportunity for 
designing new products. These technologies could find appli-
cations in the development of solvent-free injectable dosage 
forms containing drugs of low water solubility and for the 
controlled delivery of drugs (eg, antibiotics, anthelmintics) 
into beverages of breeding animals (eg, farm animals poultry, 
cattle or pigs). The strategy commonly used in food industries 
for delivering such drugs is based on the use of premix, which 
is not optimized for the different animal species, or even 
for animals of different weights. The novelty of the present 
work lies in proposing a simple method that enables the exact 
amount of drug do be determined and delivered according 
the animal species and/or body weight.
In this context, the present study aimed to adapt a low-
energy nanoemulsion formulation method that we recently 
described1,2 to such specifications. The nanoemulsion drop-
lets are spontaneously obtained very easily by bringing into 
contact a liquid phase composed of a premix of drugs, lipids, 
and surfactants, with a second phase, which is either drinking 
water or the aqueous phase that has to be injected. Nanoemul-
sions are immediately generated, allowing the dispersion of 
the poorly water-soluble drinking drug model in a definitively 
stable way in the aqueous phase. In particular, one of the 
advantages of these systems is to control the amount of drug 
administered to the animals by changing the volume of the 
premix added to the drinking water.   Obviously, these systems 
can be considered only if the premix can spontaneously form 
nanoemulsions without using external energy. For proof of 
concept, we used ketoprofen as a poorly water-soluble inject-
able drug model and sulfamethazine as poorly water-soluble 
drinking drug model. As discussed below, these two drug 
models were actually selected based on their physicochemical 
properties and their affinity for the lipophilic phases used for 
formulating the nanoemulsions.
Materials and methods
Materials
Nonionic surfactants were Cremophor ELP® (BASF, 
Ludwigshafen, Germany; polyoxyethylated-35 castor oil, 
with a specified hydrophilic–lipophilic balance [HLB] of 
12–14) and Solutol HS 15® (BASF, Ludwigshafen, Germany; 
macrogol 15 hydroxystearate, HLB of 14–16), which were 
kindly provided by Laserson (Etampes, France) and used as 
received. Labrafil M1944 CS® (oleoyl macrogolglycerides) 
and Labrafac CC® (medium chain triglycerides) were obtained 
from Gattefossé (Saint-Priest, France). Ketoprofen was 
kindly gifted by Amoli Organics Ltd. (Mumbai, India). High 
performance liquid chromatography grade ethanol, vitamin 
E acetate, sulfamethazine, and tetraglycol were purchased 
from Sigma (Saint-Louis, USA). Finally, Ultrapure® water 
was obtained using the MilliQ filtration system (Millipore, 
Saint-Quentin-en-Yvelines, France).
The different excipients were selected for their com-
patibility with the aimed administration routes, which are 
oral and parenteral. The research around these excipients 
(for instance, nonionic surfactants) was initially developed 
for human applications, and is potentially compatible with 
veterinary applications. Thus, the use of   tetraglycol in the 
modified nanoemulsification processes drug solubilization 
to be enhanced in the nanodroplets (not soluble in pure oils), 
compatibility with the parenteral administration route to be 
maintained. Tetraglycol, also called glycofurol or tetrahy-
drofurfuryl alcohol polyethyleneglycol ether (see Figure 1), 
is generally regarded as a nontoxic and nonirritant material. 
It is commonly used as a solvent in parenteral products for 
intravenous or intramuscular injection3–6 in concentrations 
up to 50% (vol/vol). The parenteral administration should 
not exceed 0.07 mL/kg body weight daily.
Low-energy nanoemulsification
The nanoemulsion droplets are generated according to a sim-
ple and efficient method, herein adapted to the encapsulation 
of 2 drugs of veterinary interest. Low-energy nanoemulsifi-
cation methods are generally described as follows: 1) spon-
taneous emulsification and 2) phase-inversion temperature. 
A detailed description of these formulation processes as well 
as a comprehensive bibliography can be found in our previous 
work2 and in the works of Salager et al7 and Solans et al.8 
However, since we have recently shown1 that these 2 methods 
are intimately linked and governed by similar mechanisms, 
we chose to focus only on spontaneous emulsification, which 
is the simplest method. The nanoencapsulation processes 
were tailored to the physicochemical properties of the mol-
O
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ecules to be encapsulated within different lipophilic phases 
(oleoyl macrogolglycerides: Labrafil M 1944 CS®, medium 
chain triglycerides: Labrafac CC®, and vitamin E acetate), 
and also with or without the use of an additional substance 
(ethanol or tetraglycol) for enhancing drug solubilization. 
As illustrated in Figure 2, the nanoemulsion droplets are 
generated by bringing two phases into contact: 1) The first 
phase is composed of oil plus the totally miscible hydrophilic 
surfactant (plus, optionally, a solvent), solubilizing the active 
principle ingredient (API); 2) The second phase is the aque-
ous one, which can be, for instance, pure water or buffer.
Once these two phases are mixed, the hydrophilic spe-
cies are immediately solubilized by the aqueous phase 
inducing the demixing of the oil (through a spinodal decom-
position) in the form of nanometric emulsion droplets. 
Surfactants immediately stabilize the nanodroplets formed. 
As presented in Figure 2, the solubilization of APIs (in red) in 
the organic oily phase (before emulsification) will result in a 
very homogeneous distribution of APIs in the   nanoemulsion 
droplets.
There are two key conditions in the nanoemulsification pro-
cess: (1) the drugs’ solubilization in the organic phase once this 
solubilization is achieved achieved, (2) this   drug-containing 
organic phase must still induce the spontaneous emulsifica-
tion process. These 2 points are thoroughly investigated in the 
present study. However, the main difficulty arises in the first 
point because the self-emulsification itself is directly linked 
to the nature of the oil–nonionic surfactant couple used (and 
their respective affinities). In this way, adapting the processes 
in the encapsulation of guest molecules will mainly involve the 
choice of these   latter molecules for the oil–nonionic surfactant 
couples available. Additional solubilizing substances, which 
can be a cosolvent, can also be used in the organic phase to 
enable the drug to be incorporated into oil.
Once the drugs are solubilized in the organic phase (the 
value of 1% wt/wt in oil is fixed throughout the study), they 
are homogenized with a vortex mixer and slowly poured into 
the slightly magnetically stirred (∼300 rpm) ultrapure water 
phase. The nanoemulsion droplets are generated within a few 
seconds. The samples were stirred for a further  15 minutes.
The different formulations were characterized by 
determining up the effect of the formulation variables 
(the relative proportions of the different components) on 
the nanoemulsions’ physicochemical properties (size and 
polydispersity index [PDI]). We have shown elsewhere1 that 
these 2 points are closely related, and changing the surfac-
tant/oil ratio, for instance, allows for a very precise control 
of the droplet size and polydispersity. The formulation 
variables are defined as follows: the solvent/oil weight ratio:   
SOR  =  100  × w surfactant /(wsurfactant  + w oil) 
and  the  surfactant–oil/water  weight  ratio: 
SOWR = 100 × w surfactant + oil /(wsurfactant + oil + w water).   
However, the SOWR has an influence only on the droplet 
concentration; thus, it was fixed at 30% throughout this 
study.
Dynamic light scattering
Hydrodynamic diameters were obtained by dynamic light 
scattering using a Malvern NanoZS instrument (Malvern, Orsay, 
France). The helium–neon laser, 4 mW, operates at 633 nm, with 
the scatter angle fixed at 173° and the temperature maintained 
at 25°C. PDI is a mathematical definition that accounts for the 
relative error between curve fit and experimental values.9 It 
shows the quality of the dispersion. Values #0.15–0.2 reflect a 
good monodispersity and quality of the nanoparticulate suspen-
sions. Measurements were performed 3 times for each point.
Results
Ketoprofen nanoencapsulation
The first example lies in the encapsulation of a model 
lipophilic drug, ketoprofen, a nonsteroidal anti-inflammatory 
drug. The study was first focused on examples of 
Oil + surfactant + API
(+ solvent)
Water
Magnetic
stirring
Figure 2 scheme of the nanoemulsion generating process. 
Abbreviation: API, active principle ingredient.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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oil–nonionic surfactant couples known for being compat-
ible with the spontaneous emulsification process.1 These 
examples are Labrafil M 1944 CS®/Cremophor ELP® and 
Labrafac CC®/Solutol HS15®. It is noteworthy that many 
possibilities exist between these families of excipients, 
and the examples studied herein are neither exhaustive nor 
representative. Point 1) mentioned regarding the drug solu-
bilization in the oily phase is rapidly achieved, showing the 
compatibility of ketoprofen with these kinds of hydrophilic 
phases. For point 2), however, the influence of drug solubi-
lization on the emulsification process itself was investigated 
by comparing nanoemulsions formed without1 and with the 
presence of drugs. The results are reported in Figures 3A 
and 3B, showing the droplet hydrodynamic diameter plotted 
against the surfactant/oil ratio denoted SOR (see Materials 
and Methods section).
The curves describe a continuous behavior from micro-
metric droplets continuously and rapidly reaching the 
nanoscale as the SOR is increased, along with a good mono-
dispersity of the samples. Also, droplet sizes and PDI can 
be controlled very easily by changing only one formulation 
parameter, SOR. Another important result is the close simi-
larity of the physicochemical properties of the drug-loaded 
nanoemulsions or nonloaded nanoemulsions, and regardless 
of the system. Furthermore, the quality of the emulsification, 
shown through the PDI, is conserved between loaded and 
nonloaded nanoemulsions.
sulfamethazine nanoencapsulation
The second example of drug nanoencapsulation uses 
sulfamethazine, which is a veterinary antibacterial drug used 
in breeding animals. This molecule was selected to illustrate 
the experimental case for which drug solubilization is not 
simply achieved in the pure oily phase but needs the help 
of an additional cosolvent. Therefore, two cosolvents were 
tested: one is ethanol used with the combination Labrafil 
M 1944 CS®/Cremophor ELP® (Figure 4); the other is tet-
raglycol, a solvent also compatible with parenteral admin-
istration (described in the Meterials and Methods section), 
used with two   examples of oil–  surfactants combinations: 
Labrafac CC®/  Cremophor ELP® (Figure 5A), and vitamin 
E acetate/Cremophor ELP® (Figure 5B).
The solubilization of sulfamethazine in the selected 
representative oil phases, which relatively differs accord-
ing to the nature of the cosolvent. Ethanol and tetraglycol 
have been shown to fulfill this objective in all the phases 
tested, which are Labrafil M 1944 CS®, Labrafac CC®, and 
vitamin E acetate.
Figure 3 Nanoemulsions formulated with low-energy spontaneous emulsification. 
A) surfactant = cremophor eLP®, oil = Labrafil M 1944 CS®. B) surfactant = solutol 
hs15, oil = Labrafac cc®. hydrodynamic diameter and polydispersity index (PDI; 
inset) are plotted against the surfactant/oil weight ratio (sOr). Nanoemulsions-
encapsulating  the  drug  (diclofenac)  are  shown  with  the  filled  circles  and 
compared with a formulation of “empty” nanoemulsions (open diamond-shaped 
symbols). The gray parts indicate that the criteria of PDI quality are not met, 
and the suspension cannot be considered as a nanoemulsion. relative standard 
deviations are comprised as follows: A) for empty nanoemulsions, between 1.5% 
and 0.2%; and for loaded nanoemulsions, between 4.3% and 3.5%; B) for empty 
nanoemulsions, between 1.3% and 0.1%; and for loaded nanoemulsions, between 
3.8% and 2.2%.
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Similar to the results obtained with ketoprofen, the 
curves show a constant gradual decrease of the nanoemulsion 
droplet size as the surfactant amount increases. Furthermore, 
the gray parts show at what point the nanodroplets form and International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 encapsulation of sulfamethazine in nanoemulsions formulated with low-
energy  spontaneous  emulsification,  with  ethanol  as  a  cosolvent.  Hydrodynamic 
diameter and polydispersity index (PDI; inset) are plotted against the surfactant/
oil weight ratio (sOr). surfactant = cremophor eLP®, oil = Labrafil M 1944 CS®. 
Oil/cosolvent weight ratio = 1. The gray part indicates that the criteria of PDI quality 
are not met, and the suspension cannot be considered as a nanoemulsion.
meet the quality criteria (low PDI). The results in Figures 4 
and 5 show that this limit can be strongly affected by the 
nature of the oil–  surfactant combinations: a SOR of around 
45% in Figure 4, and around 40% and 20% in Figures 5A 
and 5B, respectively.
Discussion
Low-energy nanoemulsification is a powerful process for 
generating stable nanodispersion of lipophilic compounds 
in an aqueous media, and at low energy costs. In addition, 
the strong interest in nanoemulsions for such applications 
also comes from their high degree of stability in suspension, 
maintained months. This stability is the consequence of the 
extremely small size of the nanoemulsion droplets which 
render the Brownian particles insensitive to the gravitational 
effect and thus to the subsequent destabilization processes 
such as flocculation (and coalescence) of concentrated 
droplets. Only Ostwald ripening (the diffusion of the dis-
persed phase through the bulk phase) acts to destabilize the 
nanoemulsion droplets,2 which is very low, and therefore 
very relevant to our intended applications. The numerous 
advantages of low-energy nanoemulsification appear when 
the process is compared with the commonly found processes 
used to generate nanoparticulate drug delivery systems, 
which are generally high-energy lipid emulsification most 
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Figure 5 encapsulation of sulfamethazine in nanoemulsions formulated with low-
energy spontaneous emulsification, with tetraglycol as a cosolvent. Hydrodynamic 
diameter and polydispersity index (PDI; inset) are plotted against the surfactant/
oil  weight  ratio  (sOr).  A)  surfactant  =  cremophor  eLP®,  oil  =  Labrafac  cc®. 
B) surfactant = cremophor eLP®, oil = vitamin e acetate. Oil/cosolvent weight 
ratio = 1. The gray parts indicate that the criteria of PDI quality are not met, and the 
suspension cannot be considered as a nanoemulsion.
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often polymeric,2 or even inorganic chemistry through, for 
instance, a sol–gel process described as a 2-step polyconden-
sation forming silica particles.10 Low-energy nanoemulsifica-
tion does not need any specific devices or chemical reactions 
for the formation of the colloidal objects: the simplicity of 
the whole process as well as a high energy yield, constitute 
significant advantages of this technology.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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However, the encapsulation of a given lipophilic active 
molecule into nanoemulsion droplets for their homogeneous 
dispersion in water has been shown to strongly depend on 
the physicochemical properties (and thus on the nature) of 
the excipients used. Indeed, it depends on the solubilization 
of such active molecules in the oil used in the nanoemulsion 
formulation, potentially with the help of a cosolvent. Accord-
ingly, the scientific approach chosen consists of adapting the 
low-energy nanoemulsification process to the molecule to be 
encapsulated, involving the use of a cosolvent for enhancing 
drug solubilization.
The formulation of lipophilic molecules is potentially 
dedicated to both parenteral and oral administration routes: 
the operator himself performs the animal injection in the 
first case, or uses a method of dispersion into the beverage 
of breeding animals. However, a important problem linked 
to the formulation of the lipophilic compounds persists with 
conventional technologies, since it is estimated that .40% 
of new pharmacologically active chemical entities identified 
by high-throughput screening have a major problem with 
their water solubility.11 In this context, low-energy nano-
emulsification technology could offer interesting solutions 
to this problem.
The two examples of molecules presented in the present 
study, ketoprofen and sulfamethazine, provide representa-
tive cases of such formulations of lipophilic compounds. 
Thus, they can show how the methodology for adapting the 
emulsification processes to the bioactive molecule proper-
ties can be applied, and illustrate how these nanoemulsi-
fication can be characterized globally (through the effect 
of the SOR on the formulation). It appears (Figure 3) that 
drug encapsulation does not influence the global nanoemul-
sion formulation in the absence of additional cosolvent, 
showing the adaptability of the method when the drug is 
easily soluble in the oily phase. However, the presence of 
a cosolvent in the formulation appears to strongly influ-
ence the process as illustrated by the difference between 
Figure 3A (solvent-free formulation) and Figure 4 (with 
ethanol as a solubilizing enhancer for sulfamethazine) for 
the same oil/surfactant combination (Labrafil M 1944 CS®/
Cremophor ELP®).
The limit in SOR for which the emulsion droplets become 
submicronic is shifted from 15% to 45%. In addition, the low 
PDIs observed, even when using a cosolvent (meaning when 
the APIs are poorly soluble in the oil), testify that the drug 
has not recrystallized in an anarchical way, but rather it is 
well encapsulated. This results in an increase in the amount 
of the surfactant in the formulations and has to be taken into 
account in the evaluation of the excipient dosage per animal. 
For the example oral formulations ie, nanoemulsions added 
to the beverages of breeding animals, the specifications only 
require the droplets to have a size below the micrometer 
dimension with high monodispersity, in order to ensure a 
high suspension stability. All the results (Figures 3–5) show 
that, this is obtained at an SOR shown by the limit between 
the gray and white areas: actually this limit could constitute 
the optimized formulation since it is a compromise that meets 
the specifications in terms of size and polydispersity, with 
the lowest amount of surfactant.
However, this so-called low-energy method means that 
the energy yields are extremely favorable for an industrial 
scale-up, since the emulsification does not need any mechani-
cal mixing. This point is all the more important for veteri-
nary compared with human applications since the orders of 
magnitude of the number of simultaneous administrations are 
significantly different. The 2 phases (organic and aqueous), 
once mixed, have to be homogenized, and this stage of the 
formulation is the only stage that needs a given (but low) 
amount of energy. A simple schematic solution is proposed 
in Figure 6.
Figure 6 shows a simple and schematic solution for the 
automated in situ emulsification and delivery of drugs in 
nanoemulsions added to beverages of breeding animals 
(domestic pigeons). The two immiscible phases are brought 
into contact through a system of 2 pipes, at constant flux. The 
proper functioning of the system is ensured by the 2 nonreturn 
valves before the emulsifying chamber. Once the emulsifica-
tion is initiated, the homogenization is performed in the next 
homogenization chamber with liquid turbulences, which are 
induced by successive changes in the liquid velocity, created 
by   successive bottlenecks in the pipe. The homogeneous 
  dispersion of drug-loaded nanoemulsions is then transported 
toward the drinking trough.
To conclude, such a technology could also be used to 
administer one or several drugs simultaneously either by 
adding a pipe or by adding a transport system. As well, one 
can imagine that one formulation developed for multiple 
applications, which either can be used for different animal 
species or can be adapted to animals of different weights (by 
changing the automated dosage instructions).
Conclusion
In this study, we present results that demonstrate the potential 
of low-energy nanoemulsification for veterinary applications. 
We present an overview of the feasibility and limits of the 
encapsulation of bioactive molecules through this technology. International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
873
Veterinary low-energy nanoemulsion
Stable suspension of
nanoemulsion droplets
encapsulating drugs
Homogenization
at constant flux
Oleic phase
+ drug
Aqueous
phase
Nonreturn
valve
Spontaneous
emulsification
by mixing
the two phases
Figure 6 Schematic design of automated in situ emulsification and delivery of drugs (red) in nanoemulsions (yellow) into beverages of breeding animals.
The general technique consists of adapting the formulation 
process to the molecule to be encapsulated, which can be 
achieved with or without the help of an additional cosolvent 
(ethanol), as well as an compatible substance that plays the 
same role (tetraglycol). Finally, this study shows the many 
advantages of the low-energy nanoemulsification method, 
specifically for veterinary applications generally involved 
in large-scale drug delivery.
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